Bavarian Nordic A/S (CPH:BAVA)(OTC: BVNRY), a biotechnology company focused on the development of innovative therapies against infectious diseases and cancer, announced on Thursday the submission by its partner, Janssen Pharmaceutical Companies of Johnson & Johnson, of Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA) seeking licensure for an investigational Ebola vaccine regimen for the prevention of Ebola Virus Disease (EVD) caused by Zaire Ebola virus.
Reportedly, two MAAs have been submitted in parallel supporting each vaccine in the two-dose regimen (Ad26.ZEBOV, MVA-BN Filo). The EMA's Committee for Medicinal Products for Human Use (CHMP) granted an Accelerated Assessment in September 2019, which will shorten the review time for these applications.
This vaccine regimen includes Ad26.ZEBOV as the first dose, which is based on Janssen's AdVac technology, and MVA-BN Filo as the second dose, which is based on Bavarian Nordic's MVA-BN technology and is administered approximately eight weeks later.
These MAAs are supported by data from phase 1, 2 and 3 clinical studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children, preclinical studies, and immunobridging analyses. To date, more than 6,500 volunteers across the US, Europe and Africa have participated in over 10 clinical studies of the vaccine.
Also, Janssen has ongoing discussions with the US Food and Drug Administration (FDA) to define the required data set for filing of the Ebola vaccine regimen under the FDA's Animal Rule licensure pathway and is also working in collaboration with the World Health Organisation (WHO) to enable registration of the Ebola vaccine regimen in African countries.
On 31 October 2019, Janssen announced that it will provide up to 500,000 regimens of its investigational vaccine to the Democratic Republic of Congo (DRC) for use in a new clinical trial organised by the DRC government and global health stakeholders in an effort to contain the country's Ebola outbreak.
Upon EMA approval of the MVA-BN Filo vaccine, Bavarian Nordic would be eligible to receive a milestone payment of USD10m under the licence agreement with Janssen.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer